ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

 

In this video, Martin Dreyling, MD, of the University of Munich in Germany, discusses results of the phase II CHRONOS-1 trial, an open-label, single-arm study evaluating the investigational PI3K inhibitor copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Dreyling highlights the mechanism of action of copanlisib, reviews response rates in the overall study population and the subset of patients with marginal zone lymphoma, and discusses the toxicity profile and future directions of study with this agent.

The data were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.